Telo Genomics Corp (TELO) AI Stock Analysis

• Market Cap: C$4.52M
• Dividend Yield: N/A
• Average Volume (3M): 29.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: 19.05%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 100,430,470
• 10 Day Avg. Volume: 22,350
• 30 Day Avg. Volume: 29,304
• PEG Ratio: 0.19
• Price to Book (P/B): 18.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.04 ▲(10.00% Upside)

The score is held down primarily by weak financial performance (pre-revenue, persistent losses, and cash burn with negative equity), with technicals also indicating a broader downtrend. Corporate events provide some positive clinical/validation progress, but valuation remains constrained by ongoing losses and no dividend support.

Positive Factors

Proprietary telomere measurement platform

Owning a single-chromosome telomere measurement platform gives the company durable IP and product differentiation in niche diagnostics and research. This supports long-term clinical partnerships, recurring service demand, and potential integration into oncology and age-related disease workflows, strengthening structural market position.

Low financial leverage

Zero reported debt materially reduces short-term solvency risk and interest burden, giving management flexibility to prioritize R&D and validation. Over 2-6 months this enhances the firm’s capacity to pursue clinical studies or non-dilutive grants before needing costly debt financing, aiding strategic options.

R&D and validation momentum

Multi-center validation and MRD-related presentations build the clinical evidence base needed for adoption and potential reimbursement talks. Sustained validation efforts improve credibility with clinicians and partners, a durable asset that supports commercialization and licensing opportunities over the medium term.

Negative Factors

Pre-revenue operations

Being pre-revenue means the business lacks operating cash inflows from customers, preventing proof of commercial product-market fit. Over months this forces reliance on financing to continue R&D and validation, delaying path to self-sustaining operations and increasing execution and dilution risk.

Persistent cash burn

Significant negative operating and free cash flow indicate ongoing funding needs to sustain R&D and validation. Without near-term revenue, continued burn pressures liquidity, forces capital raises or asset sales, and can disrupt long-term development plans and partner negotiations due to resource constraints.

Eroded shareholder equity

Transition to slightly negative equity signals accumulated losses and/or dilution have materially weakened the capital base. This impairs financial flexibility, may limit access to traditional financing, and raises governance and solvency concerns that can hinder strategic execution over the medium term.

Telo Genomics Corp Business Overview & Revenue Model

Company Description

Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.

How the Company Makes Money

Telo Genomics Corp generates revenue primarily through the commercialization of its genomic testing products and services. The company offers diagnostic tests that are used in clinical settings to aid in the detection and monitoring of diseases. Revenue streams include sales of test kits, laboratory services, and potentially licensing agreements for its proprietary technologies. Partnerships with healthcare providers, research institutions, and pharmaceutical companies are significant contributors to its earnings, allowing for broader distribution and integration of its genomic solutions into medical practice.

Telo Genomics Corp Financial Statement Overview

Summary

Telo Genomics Corp faces significant financial challenges, with no revenue generation and persistent losses. Despite a strong equity base and no debt, the ongoing negative cash flows and lack of revenue growth raise concerns about the company's long-term sustainability.

Income Statement

The income statement shows significant challenges, with zero revenue and persistent net losses over the years. Margins such as the gross profit margin and net profit margin are undefined due to the absence of revenue. The company has not demonstrated revenue growth, which is crucial for future sustainability.

Balance Sheet

The balance sheet reflects a strong equity position with no debt, leading to a favorable debt-to-equity ratio. However, equity has been decreasing over time. The equity ratio is relatively high, indicating financial stability despite ongoing losses. The absence of liabilities suggests low risk in terms of financial obligations.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, reflecting operational challenges. While the operating cash flow remains negative, indicating inefficiencies, the company has been able to secure financing, which temporarily bolsters cash reserves. However, the lack of revenue generation continues to be a major concern.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-5.64K	-14.45K	-39.54K	-33.11K	-56.96K	-62.23K
EBITDA	-2.68M	-2.69M	-2.67M	-2.78M	-2.05M	-1.01M
Net Income	-2.71M	-2.72M	-2.71M	-2.82M	-2.11M	-1.07M
Balance Sheet
Total Assets	606.90K	911.30K	965.64K	2.93M	2.83M	3.84M
Cash, Cash Equivalents and Short-Term Investments	486.51K	789.29K	796.02K	2.67M	2.69M	3.64M
Total Debt	0.00	0.00	0.00	32.50K	40.00K	40.00K
Total Liabilities	633.60K	396.32K	375.59K	312.87K	230.07K	153.66K
Stockholders Equity	-26.70K	514.98K	590.06K	2.61M	2.60M	3.69M
Cash Flow
Free Cash Flow	-2.17M	-2.33M	-2.46M	-2.70M	-1.82M	-1.11M
Operating Cash Flow	-2.16M	-2.33M	-2.46M	-2.63M	-1.79M	-1.10M
Investing Cash Flow	-5.33K	-3.25K	-5.12K	-69.06K	-25.19K	-9.31K
Financing Cash Flow	2.33M	2.33M	587.05K	2.68M	876.65K	3.83M

Telo Genomics Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.33 is Neutral, neither overbought nor oversold. The STOCH value of -16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TELO.

Telo Genomics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	47 Neutral	C$49.39M	-29.94	―	―	-21.89%	26.36%
AVCR	47 Neutral	C$8.10M	-4.97	-71.97%	―	-59.28%	-1563.64%
TELO	44 Neutral	C$4.52M	-1.66	-9999.00%	―	―	19.05%
KNE	41 Neutral	C$7.26M	-2.87	―	―	―	―
SONA	40 Underperform	C$55.37M	-17.43	-2846.90%	―	―	10.97%

Telo Genomics Corp Corporate Events

Telo Genomics Expands Multiple Myeloma MRD Validation with University of Athens Study

Telo Genomics has launched a retrospective, blood-based multiple myeloma minimal residual disease study with the University of Athens as part of its 2026 multi-center validation program for its TeloView MRD assay. The trial will leverage well-characterized patient blood samples with several years of follow-up and existing next-generation flow MRD data from both blood and bone marrow to compare prognostic performance and relapse prediction, with Telo’s assay targeting greater sensitivity and additional insight through analysis of 3D genomic architecture. This initiative, alongside ongoing prospective trials with Cleveland Clinic and Jewish General Hospital and planned additional retrospective collaborations, is intended to build a robust clinical evidence base that could support broader clinical adoption of Telo’s blood-based MRD technology and strengthen its position in the rapidly expanding global MRD testing market for multiple myeloma.

Telo Genomics Unveils Innovative Myeloma Testing at ASH Meeting

Telo Genomics Corp. presented its innovative approach to Multiple Myeloma Minimal Residual Disease testing at the 67th American Society of Hematology Meeting. The company’s method combines enumeration of circulating tumor cells with 3D telomere profiling, offering insights into disease progression and reducing the need for invasive bone marrow procedures. This advancement aligns with the growing trend in personalized healthcare and the expanding MRD testing market, which is projected to reach USD 4.1 billion by 2032. The approach could significantly impact treatment strategies and drug approval processes in the oncology field, particularly for multiple myeloma, a challenging blood cancer with a substantial treatment cost and relapse rate.

Telo Genomics Unveils Advanced MRD Technology at Myeloma Summit

Telo Genomics Corp. announced its participation in the 2025 Myeloma Canada MRD Testing Implementation Summit, where it will present its groundbreaking Minimal Residual Disease (MRD) technology. This new technology, showcased by Dr. Yulia Shifrin, offers a novel approach to MRD testing by combining blood-based workflows with the TeloView® platform, enabling risk profiling of individual cancer cells. This advancement provides a quantifiable relapse-risk score, potentially transforming clinical decision-making in multiple myeloma treatment. The MRD testing industry is poised for significant growth, with the FDA’s acceptance of MRD as a clinical endpoint for accelerated drug approvals, highlighting its importance in personalized healthcare and oncology.